Welcome Back
Join CoinTime
Sign in with email
Sign up with email
Check your inbox
GRI Bio
About
GRI Bio Inc. is a development stage biotech company.
- La Jolla,California,United States
- 1 - 10
- http://www.gribio.com/
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $255.98K
- Industries
- Biopharma,Biotechnology,Life Science,Pharmaceutical
- Founded date
- Jan 1, 2009
- Number Of Employee
- 1 - 10
- Operating Status
- Active
- Stock Symbol
- nasdaq:GRI
- Legal Name
- GRI Bio Inc.
- Also Known As
- Glycoregimmune, Inc.,Glycoregimmune,GRI
GRI is a development stage biotech company fundamentally changing the way inflammatory disease is treated. GRI’s Natural Killer T (NKT) cell-based therapies are being developed for liver disease and acute liver failure. NKT cells share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 NKT cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. GRI’s lead program, GRI-0621, is an inhibitor of type I NKT cells and is being developed as a novel oral therapeutic for acute liver failure.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 13, 2022 | IPO | — | — | — | — | Detail |
| Feb 8, 2021 | Grant | $255.98K | 1 |
National Science Foundation
|
— | Detail |
| Apr 17, 2015 | Series Unknown | $4.37M | — | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Science Foundation
|
Yes | Grant |
Employee Profiles
Acquisition
GRI Bio has acquired 1 organizations. Their most recent acquisition was GRI Bio (Reverse Merger With Vallon Pharmaceuticals) on Dec 13, 2022. They acquired GRI Bio (Reverse Merger With Vallon Pharmaceuticals) for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Dec 13, 2022
|
Biopharma | merge | — | Detail |
